Review



tram34  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Tocris tram34
    ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and <t>TRAM34</t> (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).
    Tram34, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 154 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tram34/product/Tocris
    Average 94 stars, based on 154 article reviews
    tram34 - by Bioz Stars, 2026-06
    94/100 stars

    Images

    1) Product Images from "A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities"

    Article Title: A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities

    Journal: EMBO Molecular Medicine

    doi: 10.1038/s44321-025-00237-z

    ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and TRAM34 (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).
    Figure Legend Snippet: ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and TRAM34 (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).

    Techniques Used: Fluorescence, Inhibition, Viability Assay, Derivative Assay



    Similar Products

    bath applied tram34  (Alomone Labs)
    94
    Alomone Labs bath applied tram34
    Bath Applied Tram34, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bath applied tram34/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    bath applied tram34 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    tram34  (MedChemExpress)
    94
    MedChemExpress tram34
    Tram34, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tram34/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    tram34 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    tram34  (Wulff labs)
    90
    Wulff labs tram34
    Tram34, supplied by Wulff labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tram34/product/Wulff labs
    Average 90 stars, based on 1 article reviews
    tram34 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    tram34  (Alomone Labs)
    94
    Alomone Labs tram34
    Tram34, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tram34/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    tram34 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    tram34  (Tocris)
    94
    Tocris tram34
    ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and <t>TRAM34</t> (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).
    Tram34, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tram34/product/Tocris
    Average 94 stars, based on 1 article reviews
    tram34 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    ik1 specific inhibitor tram34  (Alomone Labs)
    94
    Alomone Labs ik1 specific inhibitor tram34
    ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and <t>TRAM34</t> (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).
    Ik1 Specific Inhibitor Tram34, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ik1 specific inhibitor tram34/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    ik1 specific inhibitor tram34 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    tram34  (Danaher Inc)
    86
    Danaher Inc tram34
    ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and <t>TRAM34</t> (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).
    Tram34, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tram34/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    tram34 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and TRAM34 (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).

    Journal: EMBO Molecular Medicine

    Article Title: A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities

    doi: 10.1038/s44321-025-00237-z

    Figure Lengend Snippet: ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and TRAM34 (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).

    Article Snippet: TRAM34 , Tocris , #2946.

    Techniques: Fluorescence, Inhibition, Viability Assay, Derivative Assay